The effective activity of the dual immune checkpoint inhibition strategy (anti-PD(L)1 and anti-NKG2A) has also been more strongly confirmed by clinical trials conducted in adjuvant and neo-adjuvant settings in NSCLC patients. Here, KLRC1 is linked to non-small cell lung carcinoma.